Sun Pharmaceutical Industries is trading higher by 2.2% at Rs 836; also its new high on BSE, after Barclays Research upped its price target from Rs 760 earlier to Rs 936 and upgraded the stock to “Overweight” from “Equal Weight”.
Analyst expects the company will see meaningful launches during the next financial year 2013-14 on the back of a significant pipeline of 142 pending Abbreviated New Drug Application (ANDAs).
Meanwhile, the pharmaceutical stock has outperformed the market by gaining 12.4% in past one month compared to less than 1% gain in benchmark Sensex after reported 32% year-on-year (yoy) growth in its net profit at Rs 881 crore for the third quarter ended December 31, on the back of strong sales in the US generic market.
The stock opened at Rs 820 and touched low of Rs 817 on NSE. A combined 514,196 shares have changed hands on the counter so far on NSE and BSE.
Analyst expects the company will see meaningful launches during the next financial year 2013-14 on the back of a significant pipeline of 142 pending Abbreviated New Drug Application (ANDAs).
Meanwhile, the pharmaceutical stock has outperformed the market by gaining 12.4% in past one month compared to less than 1% gain in benchmark Sensex after reported 32% year-on-year (yoy) growth in its net profit at Rs 881 crore for the third quarter ended December 31, on the back of strong sales in the US generic market.
The stock opened at Rs 820 and touched low of Rs 817 on NSE. A combined 514,196 shares have changed hands on the counter so far on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%